
Michael Hust

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8817390/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Antibody display technologies: selecting the cream of the crop. Biological Chemistry, 2022, 403, 455-477.	2.5	71
2	Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. Hepatology, 2022, 75, 13-27.	7.3	16
3	Removing the major allergen Bra j l from brown mustard (<i>Brassica juncea</i>) by CRISPR/Cas9. Plant Journal, 2022, 109, 649-663.	5.7	22
4	MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination. Cellular and Molecular Immunology, 2022, 19, 234-244.	10.5	8
5	Immunity to SARS-CoV-2 up to 15Âmonths after infection. IScience, 2022, 25, 103743.	4.1	56
6	Phage display-based discovery of cyclic peptides against the broad spectrum bacterial anti-virulence target CsrA. European Journal of Medicinal Chemistry, 2022, 231, 114148.	5.5	3
7	Phage Display-Derived Monoclonal Antibodies Against Internalins A and B Allow Specific Detection of Listeria monocytogenes. Frontiers in Public Health, 2022, 10, 712657.	2.7	3
8	Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant. BMC Medicine, 2022, 20, 102.	5.5	67
9	Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. Nature Communications, 2022, 13, 2670.	12.8	108
10	ORFeome Phage Display Reveals a Major Immunogenic Epitope on the S2 Subdomain of SARS-CoV-2 Spike Protein. Viruses, 2022, 14, 1326.	3.3	4
11	Chemiegeschichte: Vom Gen zum Produkt. Nachrichten Aus Der Chemie, 2022, 70, 24-26.	0.0	0
12	Autoimmune encephalitis: novel therapeutic targets at the preclinical level. Expert Opinion on Therapeutic Targets, 2021, 25, 37-47.	3.4	17
13	Persistence of SARS-CoV-2-specific B and TÂcell responses in convalescent COVID-19 patients 6–8Âmonths after the infection. Med, 2021, 2, 281-295.e4.	4.4	153
14	SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface. Nature Communications, 2021, 12, 1577.	12.8	73
15	Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy. Frontiers in Cellular and Infection Microbiology, 2021, 11, 697876.	3.9	40
16	A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations. Cell Reports, 2021, 36, 109433.	6.4	75
17	Novel phage display-derived recombinant antibodies recognizing both MPT64 native and mutant (63-bp) Tj ETQq	1 <u>1 0</u> .784	314 rgBT /0
18	Catalytic ferromagnetic gold nanoparticle immunoassay for the detection and differentiation of Mycobacterium tuberculosis and Mycobacterium bovis. Analytica Chimica Acta, 2021, 1184, 339037.	5.4	6

#	Article	IF	CITATIONS
19	Validation of the Production of Antibodies in Different Formats in the HEK 293 Transient Gene Expression System. Methods in Molecular Biology, 2021, 2247, 59-76.	0.9	6
20	Investigating Alternative Container Formats for Lyophilization of Biological Materials Using Diphtheria Antitoxin Monoclonal Antibody as a Model Molecule. Pharmaceutics, 2021, 13, 1948.	4.5	1
21	Shelf-Life Extension of Fc-Fused Single Chain Fragment Variable Antibodies by Lyophilization. Frontiers in Cellular and Infection Microbiology, 2021, 11, 717689.	3.9	7
22	Generation of recombinant antibodies against human tissue kallikrein 7 to treat skin diseases. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127626.	2.2	4
23	Pyruvate dehydrogenase complex—enzyme 2, a new target for Listeria spp. detection identified using combined phage display technologies. Scientific Reports, 2020, 10, 15267.	3.3	11
24	Baculovirus-free insect cell expression system for high yield antibody and antigen production. Scientific Reports, 2020, 10, 21393.	3.3	30
25	A One-Step Process for the Construction of Phage Display scFv and VHH Libraries. Molecular Biotechnology, 2020, 62, 228-239.	2.4	19
26	Human antibodies neutralizing diphtheria toxin in vitro and in vivo. Scientific Reports, 2020, 10, 571.	3.3	52
27	Affinity-matured variants derived from nimotuzumab keep the original fine specificity and exhibit superior biological activity. Scientific Reports, 2020, 10, 1194.	3.3	6
28	Antibody Phage Display: Antibody Selection in Solution Using Biotinylated Antigens. Methods in Molecular Biology, 2020, 2070, 143-155.	0.9	10
29	Restriction-Free Construction of a Phage-Presented Very Short Macrocyclic Peptide Library. Methods in Molecular Biology, 2020, 2070, 95-113.	0.9	1
30	Parallelized Microscale Expression of Soluble scFv. Methods in Molecular Biology, 2019, 2025, 203-211.	0.9	1
31	Targeting Aspergillus fumigatus Crf Transglycosylases With Neutralizing Antibody Is Relevant but Not Sufficient to Erase Fungal Burden in a Neutropenic Rat Model. Frontiers in Microbiology, 2019, 10, 600.	3.5	19
32	Rekombinante Antikörper. , 2019, , .		1
33	Discovery of Leptospira spp. seroreactive peptides using ORFeome phage display. PLoS Neglected Tropical Diseases, 2019, 13, e0007131.	3.0	12
34	Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes. Journal of Autoimmunity, 2019, 103, 102289.	6.5	115
35	Transient plant production of Salmonella Typhimurium diagnostic antibodies. Biotechnology Reports (Amsterdam, Netherlands), 2019, 21, e00314.	4.4	11
36	Epitope Mapping via Phage Display from Single-Gene Libraries. Methods in Molecular Biology, 2019, 1904, 353-375.	0.9	9

#	Article	IF	CITATIONS
37	Human Anti-Lipopolysaccharid (LPS) antibodies against Legionella with high species specificity. Human Antibodies, 2019, 26, 29-38.	1.5	10
38	Trendbericht Biochemie 2017: Menschliche Antikörper für Medikamente. Nachrichten Aus Der Chemie, 2018, 66, 284-290.	0.0	1
39	Sequence defined antibodies improve the detection of cadherin 2 (N-cadherin) during zebrafish development. New Biotechnology, 2018, 45, 98-112.	4.4	12
40	The invasin D protein from Yersinia pseudotuberculosis selectively binds the Fab region of host antibodies and affects colonization of the intestine. Journal of Biological Chemistry, 2018, 293, 8672-8690.	3.4	573
41	Parallelized Antibody Selection in Microtiter Plates. Methods in Molecular Biology, 2018, 1701, 273-284.	0.9	39
42	Construction of Macaque Immune-Libraries. Methods in Molecular Biology, 2018, 1701, 83-112.	0.9	3
43	ORFeome Phage Display. Methods in Molecular Biology, 2018, 1701, 477-495.	0.9	8
44	Epitope Mapping by Phage Display. Methods in Molecular Biology, 2018, 1701, 497-518.	0.9	18
45	Construction of Human Immune and Naive scFv Libraries. Methods in Molecular Biology, 2018, 1701, 3-24.	0.9	12
46	Antibody Affinity and Stability Maturation by Error-Prone PCR. Methods in Molecular Biology, 2018, 1701, 393-407.	0.9	6
47	Development of Neutralizing and Non-neutralizing Antibodies Targeting Known and Novel Epitopes of TcdB of Clostridioides difficile. Frontiers in Microbiology, 2018, 9, 2908.	3.5	18
48	The Conserved Cys-2232 in Clostridioides difficile Toxin B Modulates Receptor Binding. Frontiers in Microbiology, 2018, 9, 2314.	3.5	20
49	The Binary Toxin CDT of Clostridium difficile as a Tool for Intracellular Delivery of Bacterial Glucosyltransferase Domains. Toxins, 2018, 10, 225.	3.4	20
50	Human-Like Neutralizing Antibodies Protect Mice from Aerosol Exposure with Western Equine Encephalitis Virus. Viruses, 2018, 10, 147.	3.3	22
51	Post-Exposure Protection in Mice against Sudan Virus by a Two Antibody Cocktail. Viruses, 2018, 10, 286.	3.3	16
52	Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV. MAbs, 2017, 9, 831-843.	5.2	19
53	Generation and characterization of protective antibodies to Marburg virus. MAbs, 2017, 9, 696-703.	5.2	28
54	Designing Human Antibodies by Phage Display. Transfusion Medicine and Hemotherapy, 2017, 44, 312-318.	1.6	78

#	Article	IF	CITATIONS
55	The European AntibotABE Framework Program and Its Update: Development of Innovative Botulinum Antibodies. Toxins, 2017, 9, 309.	3.4	30
56	Detection and Quantification of ADP-Ribosylated RhoA/B by Monoclonal Antibody. Toxins, 2016, 8, 100.	3.4	9
57	Neutralization of Botulinum Neurotoxin Type E by a Humanized Antibody. Toxins, 2016, 8, 257.	3.4	12
58	Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display. Proteomics - Clinical Applications, 2016, 10, 922-948.	1.6	74
59	Single Chain Antibodies as Tools to Study transforming growth factor-β-Regulated SMAD Proteins in Proximity Ligation-Based Pharmacological Screens. Molecular and Cellular Proteomics, 2016, 15, 1848-1856.	3.8	10
60	A transplant "immunome―screening platform defines a targetable epitope fingerprint of multiple myeloma. Blood, 2016, 127, 3202-3214.	1.4	7
61	Phage display-derived human antibodies in clinical development and therapy. MAbs, 2016, 8, 1177-1194.	5.2	263
62	Mining gut microbiome oligopeptides by functional metaproteome display. Scientific Reports, 2016, 6, 34337.	3.3	19
63	Selection of Recombinant Human Antibodies. Advances in Experimental Medicine and Biology, 2016, 917, 23-54.	1.6	8
64	Generation of Recombinant Antibodies Against Toxins and Viruses by Phage Display for Diagnostics and Therapy. Advances in Experimental Medicine and Biology, 2016, 917, 55-76.	1.6	17
65	Utilisation of antibody microarrays for the selection of specific and informative antibodies from recombinant library binders of unknown quality. New Biotechnology, 2016, 33, 574-581.	4.4	10
66	Identification of Novel Immunogenic Proteins of Neisseria gonorrhoeae by Phage Display. PLoS ONE, 2016, 11, e0148986.	2.5	19
67	Fructose 1,6-Bisphosphate Aldolase, a Novel Immunogenic Surface Protein on Listeria Species. PLoS ONE, 2016, 11, e0160544.	2.5	24
68	Development of Germline-Humanized Antibodies Neutralizing Botulinum Neurotoxin A and B. PLoS ONE, 2016, 11, e0161446.	2.5	21
69	Bacterial flagellar capping proteins adopt diverse oligomeric states. ELife, 2016, 5, .	6.0	46
70	Isolation of nanomolar scFvs of non-human primate origin, cross-neutralizing botulinum neurotoxins A1 and A2 by targeting their heavy chain. BMC Biotechnology, 2015, 15, 86.	3.3	9
71	Development of Human-Like scFv-Fc Neutralizing Botulinum Neurotoxin E. PLoS ONE, 2015, 10, e0139905.	2.5	21

72 Selection of Recombinant Human Antibodies. , 2015, , 23-54.

#	Article	IF	CITATIONS
73	Generation of Recombinant Antibodies Against Toxins and Viruses by Phage Display for Diagnostics and Therapy. , 2015, , 55-76.		1
74	Linear Discriminant Analysis Identifies Mitochondrially Localized Proteins in <i>Neurospora crassa</i> . Journal of Proteome Research, 2015, 14, 3900-3911.	3.7	6
75	Generation and analysis of the improved human HAL9/10 antibody phage display libraries. BMC Biotechnology, 2015, 15, 10.	3.3	115
76	Application of M13 phage display for identifying immunogenic proteins from tick (Ixodes scapularis) saliva. BMC Biotechnology, 2015, 15, 43.	3.3	23
77	Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B. MAbs, 2015, 7, 1161-1177.	5.2	25
78	Structural differences of amyloid-β fibrils revealed by antibodies from phage display. BMC Biotechnology, 2015, 15, 57.	3.3	12
79	Functional Characterization of Two scFv-Fc Antibodies from an HIV Controller Selected on Soluble HIV-1 Env Complexes: A Neutralizing V3- and a Trimer-Specific gp41 Antibody. PLoS ONE, 2014, 9, e97478.	2.5	33
80	Delivery of antibodies to the cytosol. MAbs, 2014, 6, 943-956.	5.2	67
81	The influence of antibody fragment format on phage display based affinity maturation of IgG. MAbs, 2014, 6, 204-218.	5.2	84
82	Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library. MAbs, 2014, 6, 446-459.	5.2	42
83	Human-like antibodies neutralizing Western equine encephalitis virus. MAbs, 2014, 6, 717-726.	5.2	27
84	Selection of Recombinant Antibodies from Antibody Gene Libraries. Methods in Molecular Biology, 2014, 1101, 305-320.	0.9	13
85	Cellâ€free eukaryotic systems for the production, engineering, and modification of scFv antibody fragments. Engineering in Life Sciences, 2014, 14, 387-398.	3.6	41
86	Construction of Human Antibody Gene Libraries and Selection of Antibodies by Phage Display. Methods in Molecular Biology, 2014, 1060, 215-243.	0.9	45
87	Novel human recombinant antibodies against Mycobacterium tuberculosis antigen 85B. BMC Biotechnology, 2014, 14, 68.	3.3	20
88	High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells. BMC Biotechnology, 2013, 13, 52.	3.3	172
89	Encapsulation of proteins in hydrogel carrier systems for controlled drug delivery: Influence of network structure and drug size on release rate. Journal of Biotechnology, 2013, 163, 243-249.	3.8	106
90	Production of single chain fragment variable (scFv) antibodies in Escherichia coli using the LEXâ"¢ bioreactor. Journal of Biotechnology, 2013, 163, 105-111.	3.8	23

#	Article	IF	CITATIONS
91	Identification of a new epitope for HIVâ€neutralizing antibodies in the gp41 membrane proximal external region by an Envâ€tailored phage display library. European Journal of Immunology, 2013, 43, 499-509.	2.9	16
92	Oligopeptide M13 Phage Display in Pathogen Research. Viruses, 2013, 5, 2531-2545.	3.3	33
93	Expression of Recombinant Antibodies. Frontiers in Immunology, 2013, 4, 217.	4.8	249
94	Recombinant antibody fragments allow repeated measurements of C-reactive protein with a quartz crystal microbalance immunosensor. MAbs, 2013, 5, 140-149.	5.2	8
95	Identification of immunogenic proteins and generation of antibodies against SalmonellaTyphimurium using phage display. BMC Biotechnology, 2012, 12, 29.	3.3	31
96	Construction of Human Naive Antibody Gene Libraries. Methods in Molecular Biology, 2012, 907, 85-107.	0.9	20
97	Isolation and Characterisation of a Human-Like Antibody Fragment (scFv) That Inactivates VEEV In Vitro and In Vivo. PLoS ONE, 2012, 7, e37242.	2.5	41
98	Generating Recombinant Antibodies for Research, Diagnostics and Therapy Using Phage Display. Current Biotechnology, 2012, 1, 33-41.	0.4	18
99	Human antibodies targeting CD30+ lymphomas. Human Antibodies, 2012, 21, 13-28.	1.5	10
100	Suppression of p75 Neurotrophin Receptor Surface Expression with Intrabodies Influences Bcl-xL mRNA Expression and Neurite Outgrowth in PC12 Cells. PLoS ONE, 2012, 7, e30684.	2.5	25
101	Development of Human and Macaque Antibodies Using Antibody Phage Display for the Detection of Equine Encephalitis Viruses. , 2011, , .		Ο
102	Phage Display for the Generation of Antibodies for Proteome Research, Diagnostics and Therapy. Molecules, 2011, 16, 412-426.	3.8	96
103	Isolation of scFv fragments specific to OmpD of Salmonella Typhimurium. Veterinary Microbiology, 2011, 147, 162-169.	1.9	28
104	Antibody production in <i>Bacillus megaterium</i> : Strategies and physiological implications of scaling from microtiter plates to industrial bioreactors. Biotechnology Journal, 2011, 6, 1516-1531.	3.5	20
105	Influence of the hydromechanical stress and temperature on growth and antibody fragment production with Bacillus megaterium. Applied Microbiology and Biotechnology, 2011, 91, 81-90.	3.6	14
106	Isolation of a nanomolar scFv inhibiting the endopeptidase activity of botulinum toxin A, by single-round panning of an immune phage-displayed library of macaque origin. BMC Biotechnology, 2011, 11, 113.	3.3	22
107	Efficient production of soluble recombinant single chain Fv fragments by a Pseudomonas putida strain KT2440 cell factory. Microbial Cell Factories, 2011, 10, 11.	4.0	45
108	A human scFv antibody generation pipeline for proteome research. Journal of Biotechnology, 2011, 152, 159-170.	3.8	127

#	Article	IF	CITATIONS
109	Rise and Fall of an Anti-MUC1 Specific Antibody. PLoS ONE, 2011, 6, e15921.	2.5	73
110	Oligomeric forms of single chain immunoglobulin (sclgG). MAbs, 2010, 2, 73-76.	5.2	15
111	Towards proteome scale antibody selections using phage display. New Biotechnology, 2010, 27, 118-128.	4.4	53
112	Generating recombinant antibodies to the complete human proteome. Trends in Biotechnology, 2010, 28, 333-339.	9.3	98
113	Phage display-based identification and potential diagnostic application of novel antigens from Mycoplasma mycoides subsp. mycoides small colony type. Veterinary Microbiology, 2010, 142, 285-292.	1.9	22
114	Minimum information about a protein affinity reagent (MIAPAR). Nature Biotechnology, 2010, 28, 650-653.	17.5	50
115	Human Antibody Gene Libraries. , 2010, , 65-84.		5
116	Immune Libraries from Nonhuman Primates (NHP). , 2010, , 99-114.		0
117	Improving Phage Display Throughput by Using Hyperphage, Miniaturized Titration and pVIII (g8p) ELISA. , 2010, , 197-206.		2
118	Construction of Human Antibody Gene Libraries and Selection of Antibodies by Phage Display. Methods in Molecular Biology, 2010, 651, 177-209.	0.9	51
119	Phage Display and Selection in Microtitre Plates. , 2010, , 139-149.		1
120	Affinity Maturation by Phage Display. Methods in Molecular Biology, 2009, 525, 309-322.	0.9	46
121	Functional knockdown of VCAM-1 at the posttranslational level with ER retained antibodies. Journal of Immunological Methods, 2009, 341, 30-40.	1.4	22
122	Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity. BMC Biotechnology, 2009, 9, 60.	3.3	82
123	Improved microtitre plate production of single chain Fv fragments in Escherichia coli. New Biotechnology, 2009, 25, 424-428.	4.4	43
124	Obtention and Engineering of Non-Human Primate (NHP) Antibodies for Therapeutics. Mini-Reviews in Medicinal Chemistry, 2009, 9, 1633-1638.	2.4	23
125	Antibody Production by the Gram-Positive Bacterium Bacillus megaterium. Methods in Molecular Biology, 2009, 525, 509-516.	0.9	5
126	Identification of a Putative Crf Splice Variant and Generation of Recombinant Antibodies for the Specific Detection of Aspergillus fumigatus. PLoS ONE, 2009, 4, e6625.	2.5	63

#	Article	IF	CITATIONS
127	SRP and Sec pathway leader peptides for antibody phage display and antibody fragment production in E. coli. New Biotechnology, 2008, 25, 49-54.	4.4	53
128	Identification of immunogenic polypeptides from a Mycoplasma hyopneumoniae genome library by phage display. Applied Microbiology and Biotechnology, 2008, 80, 447-58.	3.6	33
129	Development of human antibody fragments using antibody phage display for the detection and diagnosis of Venezuelan equine encephalitis virus (VEEV). BMC Biotechnology, 2008, 8, 66.	3.3	73
130	Production systems for recombinant antibodies. Frontiers in Bioscience - Landmark, 2008, Volume, 4576.	3.0	75
131	Phage Display Derived Therapeutic Antibodies. Current Pharmaceutical Biotechnology, 2008, 9, 439-446.	1.6	84
132	High-Affinity, Human Antibody-Like Antibody Fragment (Single-Chain Variable Fragment) Neutralizing the Lethal Factor (LF) of Bacillus anthracis by Inhibiting Protective Antigen-LF Complex Formation. Antimicrobial Agents and Chemotherapy, 2007, 51, 2758-2764.	3.2	105
133	On the influence of vector design on antibody phage display. Journal of Biotechnology, 2007, 127, 626-637.	3.8	90
134	Selection of Recombinant Antibodies From Antibody Gene Libraries. Methods in Molecular Biology, 2007, 408, 243-255.	0.9	30
135	Production of recombinant antibody fragments in Bacillus megaterium. Microbial Cell Factories, 2007, 6, 2.	4.0	44
136	Production of single chain Fab (scFab) fragments in Bacillus megaterium. Microbial Cell Factories, 2007, 6, 38.	4.0	26
137	Single chain Fab (scFab) fragment. BMC Biotechnology, 2007, 7, 14.	3.3	113
138	Enrichment of open reading frames presented on bacteriophage M13 using Hyperphage. BioTechniques, 2006, 41, 335-342.	1.8	45
139	Parameters affecting the display of antibodies on phage. Journal of Immunological Methods, 2005, 301, 173-185.	1.4	54
140	Perspectives for systematic in vitro antibody generation. Gene, 2005, 364, 19-29.	2.2	71
141	Phage Display Vectors for the In Vitro Generation of Human Antibody Fragments. , 2005, 295, 71-96.		38
142	Mating antibody phage display with proteomics. Trends in Biotechnology, 2004, 22, 8-14.	9.3	134
143	A methodological approach to investigate steady state fucoxanthin chlorophyll a/c binding protein mRNA levels in Wadden Sea sediments. International Microbiology, 2003, 6, 33-39.	2.4	4
144	The production of a genus-specific recombinant antibody (scFv) using a recombinant potyvirus protease. Journal of Virological Methods, 2002, 106, 225-233.	2.1	57

#	Article	IF	CITATIONS
145	An immunochemical in situ approach to detect adaptation processes in the photosynthetic apparatus of diatoms of the Wadden Sea sediment surface layers. Journal of Microbiological Methods, 1999, 38, 69-80.	1.6	5